glp 1 drugs for perimenopause GLP-1 Agonists in Perimenopause: Unique Risks and Potential Opportunities GLP-1 for Perimenopause Weight Loss:

doi:10.1016/j.addr.2018.07.009 6

Average 15-21% weight loss* Tailored programmes built by real experts Targeted support to make success feel simpler Unique app with weight loss tools and lessons Your journey starts here Start your personalised weight loss plan in minutes

At the higher doses, results were very consistent: All participants lost at least 5% of their body weight Around 3 in 4 lost 15% or more With placebo, only around 1 in 4 lost 5% or more Phase 3 update (TRIUMPH-4, 68 weeks, topline results) In December 2025 , Eli Lilly shared early (topline) results from a larger phase 3 study (TRIUMPH-4)

Thus, the use of combination pharmacotherapy involving other molecules in addition to gut hormones seems to be a plausible approach to treating the metabolic syndrome

The analysis included 25 trials published between 1966 and 2002, with a total of 4874 participants

On Day 11, peripheral organs (heart, spleen, kidney, pancreas, liver, mesenteric, perirenal and epididymal white adipose tissue, interscapular brown adipose tissue) were collected and their wet organ weights measured